S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Forecast, Price & News

$1.52
-0.05 (-3.18%)
(As of 04:25 PM ET)
Compare
Today's Range
$1.50
$1.64
50-Day Range
$1.41
$2.31
52-Week Range
$1.25
$5.64
Volume
773,813 shs
Average Volume
1.43 million shs
Market Capitalization
$153.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00

Atara Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,733.1% Upside
$28.00 Price Target
Short Interest
Bearish
11.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.45mentions of Atara Biotherapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$102,303 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.60) to ($1.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

229th out of 963 stocks

Biological Products, Except Diagnostic Industry

30th out of 159 stocks


ATRA stock logo

About Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

ATRA Price History

ATRA Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
10 Most Promising Penny Stocks According to Analysts
Atara Biotherapeutics's Earnings Outlook
See More Headlines
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATRA
Fax
N/A
Employees
317
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.00
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+1,730.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-228,300,000.00
Net Margins
-4,437.45%
Pretax Margin
-4,436.94%

Debt

Sales & Book Value

Annual Sales
$63.57 million
Book Value
$1.33 per share

Miscellaneous

Free Float
96,552,000
Market Cap
$154.68 million
Optionable
Optionable
Beta
1.03
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Pascal Touchon D.V.M. (Age 60)
    Pres, CEO & Director
    Comp: $1.08M
  • Mr. K. Amar MuruganMr. K. Amar Murugan (Age 47)
    Exec. VP & Chief Legal Officer
    Comp: $618.52k
  • Dr. Jakob Dupont M.D. (Age 58)
    Consultant
    Comp: $750.53k
  • Mr. Eric Hyllengren (Age 48)
    Sr. VP & CFO
  • Dr. Anhco Nguyen Ph.D. (Age 50)
    Exec. VP and Chief Scientific & Technical Officer
  • Kerry Beth Daly
    Head of Corp. Communications
  • Mr. Joseph NewellMr. Joseph Newell (Age 53)
    Exec. VP
  • Dr. Manher Joshi M.D.
    Exec. VP & Chief Medical Officer
  • Ms. Jill Henrich (Age 60)
    Exec. VP and Global Head of Regulatory Affairs & Quality
  • Mr. Dan Maziasz
    Exec. VP & Chief Bus. Officer













ATRA Stock - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRA shares.
View ATRA analyst ratings
or view top-rated stocks.

What is Atara Biotherapeutics' stock price forecast for 2023?

3 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $25.00 to $31.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 1,730.1% from the stock's current price.
View analysts price targets for ATRA
or view top-rated stocks among Wall Street analysts.

How have ATRA shares performed in 2023?

Atara Biotherapeutics' stock was trading at $3.28 on January 1st, 2023. Since then, ATRA shares have decreased by 53.4% and is now trading at $1.53.
View the best growth stocks for 2023 here
.

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ATRA earnings forecast
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.03. The biotechnology company had revenue of $0.96 million for the quarter, compared to analyst estimates of $3.36 million. Atara Biotherapeutics had a negative net margin of 4,437.45% and a negative trailing twelve-month return on equity of 315.45%.

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baupost Group LLC MA (9.67%), Wasatch Advisors LP (8.46%), BlackRock Inc. (8.17%), JPMorgan Chase & Co. (7.64%), Goldman Sachs Group Inc. (4.51%) and State Street Corp (2.51%). Insiders that own company stock include Amar Murugan, Eric J Hyllengren, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends
.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $1.53.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $154.68 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

The company employs 317 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com.

This page (NASDAQ:ATRA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -